These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Lorcy Y; Dejager S; Chanson P; Pituitary; 2000 Nov; 3(3):193-7. PubMed ID: 11383486 [TBL] [Abstract][Full Text] [Related]
25. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615 [TBL] [Abstract][Full Text] [Related]
26. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Sheppard M; Bronstein MD; Freda P; Serri O; De Marinis L; Naves L; Rozhinskaya L; Hermosillo Reséndiz K; Ruffin M; Chen Y; Colao A Pituitary; 2015 Jun; 18(3):385-94. PubMed ID: 25103549 [TBL] [Abstract][Full Text] [Related]
27. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408 [TBL] [Abstract][Full Text] [Related]
28. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188 [TBL] [Abstract][Full Text] [Related]
29. Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. Postma MR; Netea-Maier RT; van den Berg G; Homan J; Sluiter WJ; Wagenmakers MA; van den Bergh AC; Wolffenbuttel BH; Hermus AR; van Beek AP Eur J Endocrinol; 2012 Apr; 166(4):585-92. PubMed ID: 22250074 [TBL] [Abstract][Full Text] [Related]
30. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. Serri O; Beauregard C; Hardy J J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777 [TBL] [Abstract][Full Text] [Related]
31. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586 [TBL] [Abstract][Full Text] [Related]
32. Glycemic profile in patients with acromegaly treated with somatostatin analogue. Valea A; Carsote M; Ghervan C; Georgescu C J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517 [TBL] [Abstract][Full Text] [Related]
33. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. Auriemma RS; Galdiero M; Grasso LF; Vitale P; Cozzolino A; Lombardi G; Colao A; Pivonello R Eur J Endocrinol; 2010 May; 162(5):993-9. PubMed ID: 20156970 [TBL] [Abstract][Full Text] [Related]
34. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly. Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168 [TBL] [Abstract][Full Text] [Related]
35. Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Giordano C; Ciresi A; Amato MC; Pivonello R; Auriemma RS; Grasso LF; Galluzzo A; Colao A Pituitary; 2012 Dec; 15(4):539-51. PubMed ID: 22116639 [TBL] [Abstract][Full Text] [Related]
36. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045 [TBL] [Abstract][Full Text] [Related]
37. Clinical and metabolic characteristics of acromegalic patients with high IGF1/normal GH levels during somatostatin analog treatment. Matta M; Bongard V; Grunenwald S; Maiza JC; Bennet A; Caron P Eur J Endocrinol; 2011 Jun; 164(6):885-9. PubMed ID: 21471168 [TBL] [Abstract][Full Text] [Related]
38. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. Giusti M; Gussoni G; Cuttica CM; Giordano G J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833 [TBL] [Abstract][Full Text] [Related]
39. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Tutuncu Y; Berker D; Isik S; Ozuguz U; Akbaba G; Kucukler FK; Aydin Y; Guler S Pituitary; 2012 Sep; 15(3):398-404. PubMed ID: 21863263 [TBL] [Abstract][Full Text] [Related]
40. Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients. Christiansen Arlien-Søborg M; Trolle C; Alvarson E; Bæk A; Dal J; Otto Lunde Jørgensen J Endocrine; 2017 Jun; 56(3):589-594. PubMed ID: 28260207 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]